RecruitingNCT06044662
Prognostic Value of Biomarkers in Polyneuropathy.
The Prognostic Value of Blood Biomarkers for Patients With Polyneuropathy.
Sponsor
Rigshospitalet, Denmark
Enrollment
200 participants
Start Date
Oct 27, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Biomarkers for prognosis of patients with polyneuropathy.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Minimum 18 years old.
- Diagnosed with polyneuropathy, confirmed by nerve conduction study.
- Can read and understand Danish.
Exclusion Criteria1
- Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06044662
Related Trials
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT0656389598 locations
Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
NCT071663022 locations
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
NCT063770331 location
Diagnostic Feasibility of 100 Hz Tetanic Stimulation
NCT067549952 locations
Exploring the Genetics of Neuropathic Pain
NCT038623655 locations